Starling Oncology, Inc. Contract Liability (Deferred Revenue)
Starling Oncology, Inc. (STLN) had Contract Liability (Deferred Revenue) of $2.28 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-03-12
- 2025-12-31: Contract with Customer, Liability, Current $2.28M.
- 2025-09-30: Contract with Customer, Liability, Current $4.90M.
- 2025-06-30: Contract with Customer, Liability, Current $5.20M.
- 2025-03-31: Contract with Customer, Liability, Current $4.08M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-12-31 | $2.28M 10-K · filed 2026-03-12 |
| 2025-09-30 | $4.90M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $5.20M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $4.08M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.35M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.38M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $861.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $964.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $545.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $545.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $610.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $875.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $1.14M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.28M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.35M 10-Q · filed 2022-08-09 |
| 2021-12-31 | $262.00K 10-K · filed 2023-03-16 |